Cln2 (yN-19): sc-6692



The Power to Question

BACKGROUND

Cell cycle progression is controlled at a point late in G1 designated Start. Passage through Start requires the activity of the cyclin-dependent protein kinase Cdc28. Transition from G1 to S phase requires the association of Cdc28 with members of the G1 cyclin family, including Cln1, Cln2 and Cln3 (also designated Daf1 or Whi1). The G2 to M phase requires the M phase cyclins, Clb1 (also designated Scb1) and Clb2, as well as the G2 cyclins, Clb3 and Clb4. The S phase cyclins Clb5 and Clb6 coordinate DNA replication with cytokinesis. Expression of the cyclins is controlled by UBC9 and Cdc34 (also designated Ubc3 or Dna6) via ubiquitin-mediated proteolysis.

REFERENCES

- Nasmyth, K. 1993. Control of the yeast cell cycle by the Cdc28 protein kinase. Curr. Opinion Cell Biol. 5: 166-179.
- Sherlock, G. and Rosamond, J. 1993. Starting to cycle: G1 controls regulating cell division in budding yeast. J. Gen. Microbiol. 139: 2531-2541.
- Amon, A., Tyers, M., Futcher, B., and Nasmyth, K. 1993. Mechanisms that help the yeast cell cycle clock tick: G2 cyclins transcriptionally activate G2 cyclins and repress G1 cyclins. Cell 74: 993-1007.
- Basco, R.D., Segal, M.D., and Reed., S.I. 1995. Negative regulation of G1 and G2 by S-phase cyclins of *Saccharomyces cerevisiae*. Mol. Cell. Biol. 15: 5030-5042.
- Seufert, W., Futcher, B., and Jentsch, S. 1995. Role of a ubiquitin-conjugating enzyme in degradation of S- and M- phase cyclins. Nature 373: 78-81.
- Prendergast, J.A., Ptak, C., Arnason, T.G., and Ellison, M.J. 1995. Increased ubiquitin expression suppresses the cell cycle defect associated with the yeast ubiquitin conjugating enzyme, CDC34 (UCB3). Evidence for a noncovalent interaction between CDC34 and ubiquitin. J. Biol. Chem. 270: 9347-9352.
- Levine, K., Huang, K., and Cross, F.R. 1996. Saccharomyces cerevisiae G1 cyclins differ in their intrinsic functional specificities. Mol. Cell. Biol. 16: 6794-6803.
- 8. Blondel, M. and Mann, C. 1996. G2 cyclins are required for the degradation of G1 cyclins in yeast. Nature 384: 279-282.

SOURCE

Cln2 (yN-19) is an affinity purified goat polyclonal antibody raised against a peptide mapping at the N-terminus of Cln2 of *Saccharomyces cerevisiae* origin.

PRODUCT

Each vial contains 200 μg IgG in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

Blocking peptide available for competition studies, sc-6692 P, (100 μ g peptide in 0.5 ml PBS containing < 0.1% sodium azide and 0.2% BSA).

RESEARCH USE

For research use only, not for use in diagnostic procedures.

APPLICATIONS

Cln2 (yN-19) is recommended for detection of Cln2 of *Saccharomyces cerevisiae* origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000) and solid phase ELISA (starting dilution 1:30, dilution range 1:30-1:3000).

RECOMMENDED SECONDARY REAGENTS

To ensure optimal results, the following support (secondary) reagents are recommended: 1) Western Blotting: use donkey anti-goat IgG-HRP: sc-2020 (dilution range: 1:2000-1:100,000) or Cruz Marker™ compatible donkey anti-goat IgG-HRP: sc-2033 (dilution range: 1:2000-1:5000), Cruz Marker™ Molecular Weight Standards: sc-2035, TBS Blotto A Blocking Reagent: sc-2333 and Western Blotting Luminol Reagent: sc-2048.

STORAGE

Store at 4° C, **DO NOT FREEZE**. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

PROTOCOLS

See our web site at www.scbt.com or our catalog for detailed protocols and support products.

Santa Cruz Biotechnology, Inc. 1.800.457.3801 831.457.3801 fax 831.457.3801 Europe +00800 4573 8000 49 6221 4503 0 www.scbt.com